🏛️ Verified NIH Record • Updated 2025-12-04
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500)
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Mayo Clinic — Phoenix, Arizona
- Sarah Cannon Research Institute (SCRI) - HealthONE Location — Denver, Colorado
- Rocky Mountain Cancer Centers, LLP - Oncology — Lone Tree, Colorado
- Mayo Clinic — Jacksonville, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
- Local Institution - 124 — Chicago, Illinois
- Dana-Farber Cancer Institute — Brookline, Massachusetts
- Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan
- Mayo Clinic — Rochester, Minnesota
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Local Institution - 129 — Mineola, New York
- David H Koch, Memorial Sloan Kettering Cancer Center — New York, New York
- New york cancer and blood specialists - Oncology — Port Jefferson Station, New York
- New york cancer and blood specialists - Oncology — Port Jefferson Station, New York
- University of North Carolina - Gastroenterology and Hepatology — Chapel Hill, North Carolina
- University of North Carolina — Chapel Hill, North Carolina
- Vanderbilt - Ingram Cancer Center — Nashville, Tennessee
- Ut Southwestern — Dallas, Texas
- Texas Oncology - DFW — Fort Worth, Texas
- MDACC — Houston, Texas
- South Texas Accelerated Research Therapeutics — San Antonio, Texas
- Texas Oncology, P.A. - Oncology — Tyler, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Local Institution - 134 — Seattle, Washington
- Local Institution - 108 — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Los Angeles, California
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma — Tampa, Florida
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer — San Francisco, California
- Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.